Prognosis in primary effusion lymphoma is associated with the number of body cavities involved
- 13 June 2012
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 53 (12) , 2378-2382
Abstract
Primary effusion lymphoma (PEL) is a rare lymphoma associated with Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), and characterized by a malignant body cavity effusion without solid organ or nodal involvement. Prognostic factors in patients with PEL have not been systematically studied. We conducted a literature search for patients with HHV8-positive PEL to identify potential prognostic factors for survival. Our search identified 147 patients, among which 104 patients were HHV8-positive. The median overall survival was 9 months. The median age was 57 years with a male predominance (6:1). Pathologically, 33% of the patients expressed CD20 and 69% expressed CD30. Patients with PEL with > 1 body cavity involved had a median overall survival (OS) of 4 months compared with 18 months in patients with only one cavity involved (p = 0.003). Additionally, in patients with one involved body cavity, pericardial involvement was associated with a longer median OS than pleural followed by peritoneal involvement (40, 27 and 5 months, respectively; p = 0.04). In conclusion, our study suggests that the number and location of body cavities involved are prognostic in patients with PEL.Keywords
This publication has 26 references indexed in Scilit:
- Elevation of clonal serum free light chains in patients with HIV‐negative primary effusion lymphoma (PEL) and PEL‐like lymphomaBritish Journal of Haematology, 2009
- Human Herpesvirus-8 (HHV-8)-Associated Primary Effusion Lymphoma in two Renal Transplant Recipients Receiving RapamycinAmerican Journal of Transplantation, 2008
- Primary Effusion LymphomaThe Oncologist, 2007
- Accumulation of Heterochromatin Components on the Terminal Repeat Sequence of Kaposi's Sarcoma-Associated Herpesvirus Mediated by the Latency-Associated Nuclear AntigenJournal of Virology, 2004
- A novel viral mechanism for dysregulation of β-catenin in Kaposi's sarcoma–associated herpesvirus latencyNature Medicine, 2003
- The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma–E2F pathway and with the oncogene Hras transforms primary rat cellsNature Medicine, 2000
- p53 inhibition by the LANA protein of KSHV protects against cell deathNature, 1999
- Efficient Persistence of Extrachromosomal KSHV DNA Mediated by Latency-Associated Nuclear AntigenScience, 1999
- Human Herpesvirus 8 (HHV-8) in the Pathogenesis of Kaposi's Sarcoma and Other DiseasesLeukemia & Lymphoma, 1998
- Kaposi's Sarcoma–Associated Herpesvirus-Like DNA Sequences in AIDS-Related Body-Cavity–Based LymphomasNew England Journal of Medicine, 1995